Date | Open(₹) | High(₹) | Low(₹) | Close(₹) | No. Of Trades(₹) | Total Turnover(₹) | Deliverable Quantity(₹) |
|---|---|---|---|---|---|---|---|
11-Mar-2026 | 458.75 | 463.43 | 452.75 | 459.25 | 6,717 | 8,63,90,287 | 23,360 |
12-Mar-2026 | 461.23 | 462.25 | 450 | 455.98 | 6,924 | 5,58,89,894.3 | 15,092 |
13-Mar-2026 | 456.25 | 458.75 | 450.25 | 452.15 | 5,410 | 27,78,12,176.5 | 1,43,412 |
16-Mar-2026 | 455.25 | 478.5 | 451.55 | 459.85 | 16,628 | 15,81,37,755.8 | 22,457 |
17-Mar-2026 | 462 | 465.25 | 453.48 | 464.5 | 6,026 | 6,01,69,648.8 | 16,551 |
18-Mar-2026 | 468 | 473.5 | 463.25 | 466.98 | 11,765 | 15,57,60,288.9 | 55,848 |
19-Mar-2026 | 463.75 | 463.75 | 453 | 455.95 | 6,592 | 9,24,85,688.4 | 31,156 |
20-Mar-2026 | 470 | 474 | 436 | 441.1 | 27,394 | 21,79,57,215.2 | 1,33,416 |
23-Mar-2026 | 434.5 | 475 | 421.2 | 450.2 | 11,706 | 8,50,96,060 | 63,571 |
24-Mar-2026 | 448 | 472 | 432.5 | 443 | 32,019 | 16,85,01,553.9 | 1,24,398 |
25-Mar-2026 | 438.3 | 445.7 | 426.1 | 438.8 | 33,771 | 38,87,62,612.5 | 4,79,369 |
27-Mar-2026 | 433 | 438.6 | 427.3 | 430.8 | 36,622 | 53,20,67,129 | 9,39,712 |
30-Mar-2026 | 426.1 | 436.7 | 414.2 | 434 | 17,065 | 10,04,30,298.3 | 1,02,642 |
01-Apr-2026 | 444 | 444 | 420.3 | 424.25 | 16,600 | 10,71,74,643.05 | 99,207 |
02-Apr-2026 | 415.25 | 430.9 | 412.25 | 421.75 | 17,559 | 23,70,51,818.5 | 3,93,955 |
06-Apr-2026 | 433 | 441.8 | 422 | 430.75 | 32,559 | 56,79,65,714.9 | 4,18,356 |
07-Apr-2026 | 425.05 | 438.25 | 425.05 | 434.4 | 12,398 | 7,57,26,556.7 | 68,746 |
08-Apr-2026 | 444 | 460.85 | 429.15 | 456 | 17,540 | 19,05,79,421.85 | 2,40,147 |
09-Apr-2026 | 455.9 | 459.7 | 447.5 | 456.9 | 9,468 | 3,65,88,804.45 | 28,078 |
Metropolis Healthcare said it plans to expand its genomic test portfolio to more than 500 advanced tests over the next two to three years
The deal includes a deferred payment of ₹1.7 crore, which will be disbursed as per the terms of the business transfer agreement, the company said in a regulatory filing.
The EBITDA margin fell to 18% in Q4 FY25 from 24.2% in Q4 FY24, reflecting a fall in operational efficiency or profitability.
The EBITDA margin was stable at 22.3% and did not change much from the year-ago period.
This is a 100% stake purchase that will be funded through 55% cash and 45% equity swap. It expects completion in 60 days, after shareholders give their nod.
Here are some of the stocks that may see significant price movement today: Tata Motors, Asian Paints, Divi’s Laboratories, etc.
Here are some of the stocks that may see significant price movement today: Titan Company, HDFC Bank, IndusInd Bank, etc.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2026, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund & Specialized Investment Fund Distributor), PFRDA Reg. No. PoP 20092018
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
